Compare RVLV & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVLV | AMLX |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2018 | 2021 |
| Metric | RVLV | AMLX |
|---|---|---|
| Price | $18.42 | $12.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $29.73 | $21.56 |
| AVG Volume (30 Days) | ★ 1.3M | 933.3K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.64 | ★ 65.46 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $1,225,682,000.00 | $380,786,000.00 |
| Revenue This Year | $10.96 | N/A |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | $91.55 | ★ N/A |
| Revenue Growth | 8.48 | ★ 1612.94 |
| 52 Week Low | $17.35 | $4.64 |
| 52 Week High | $31.68 | $18.61 |
| Indicator | RVLV | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 28.92 | 27.71 |
| Support Level | $18.08 | $12.13 |
| Resistance Level | $22.53 | $15.37 |
| Average True Range (ATR) | 1.29 | 0.77 |
| MACD | -0.47 | -0.40 |
| Stochastic Oscillator | 11.02 | 5.78 |
Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.